

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

1-50. (Canceled)

51. (Currently Amended) An isolated antibody ~~capable of binding~~ which binds to a human CCR5 chemokine receptor on the surface of a CD4+ cell and ~~inhibiting~~ inhibits HIV-1 infection of such CD4+ cell.

52. (Canceled)

53. (Currently Amended) The antibody of claim 51 ~~or~~ 52, wherein the CD4+ cell is a PM-1 cell.

54. (Currently Amended) The antibody of claim 51 ~~or~~ 52, wherein the CD4+ cell is a primary CD4+ T-cell.

55. (Currently Amended) The antibody of claim 51 ~~or~~ 52, wherein the CD4+ cell is a peripheral blood mononuclear cell (PBMC).

56. (Currently Amended) The antibody of claim 51 ~~or~~ 52, wherein the antibody is a monoclonal antibody.

57. (Currently Amended) A pharmaceutical composition comprising the antibody ~~any of claims of claim~~ of claim 51, 52 or 56 and a pharmaceutically acceptable carrier.

Applicants: Graham P. Allaway et al.
U.S. Serial No.: 09/888,938
Filed: June 25, 2001
Page 3

58. (Previously Presented) The pharmaceutical composition of claim 57, wherein the antibody is present in an amount effective to inhibit HIV-1 infection.